A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] and peginterferon alfa-2a [Pegasys] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 18 sites in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-07-11.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 14th largest by enrollment, is one of 12 that started in 2003, is one of 48 in phase 4, and was the 55th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 12 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 395 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2003, is one of 29 in phase 4, and was the 43rd registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, parallel arm study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in combination with 2 different doses of ribavirin in patients with chronic hepatitis C, genotype 2 or 3. Patients will be randomized to 4 treatment groups receiving Pegasys (180 mcg subcutaneously weekly) for either 16 or 24 weeks with one of two doses of ribavirin (400 mg or 800 mg orally daily). The anticipated time on study treatment is 16 or 24 weeks with a 24-week follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).
Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin
Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.
Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin
Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.
Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin
Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.
Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin
Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment
Sustained virological response was defined as the percentage of participants in each group with undetectable Hepatitis C virus-Ribonucleic acid (HCV-RNA) measurement at 24 weeks post completion of the treatment.
Time frame: Up to Week 48 (24 weeks post completion of the treatment)
Percentage of Participants With Hepatitis C Virus-RNA Determined by AMPLICOR HCV Test At Week 24 and Week 48
Serum Hepatitis C Virus-RNA (HCV-RNA) was done by Polymerase chain reaction (PCR). Samples for a qualitative PCR (AMPLICOR® HCV Test v2.0) were obtained at Week 24 and Week 48. 'G2' and 'G3' indicates Genotype 2 and Genotype 3 respectively.
Time frame: At Week 24 and Week 48
Percentage of Participants With Virological Response at the End of the Treatment
Virological response at the end of the treatment (ETR) was defined as the percentage of participants with negative qualitative PCR in each group at completion of the treatment. ETR is defined as Week 16 and Week 24.
Time frame: At Week 16 and Week 24
Percentage of Participants With Virologic Response Rates as Per Genotype at End of Treatment
Virologic Response was defined as undetectable HCV-RNA levels (determined by AMPLICOR HCV test) at Week 16 and Week 24. Virologic response rates based on genotype (G2 and G3) were reported. ETR is defined as Week 16 and Week 24.
Time frame: At Week 16 and Week 24
Number of Participants With Any Adverse Events and Any Serious Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
Time frame: Up to Week 48
Median Hemoglobin Levels at End of Treatment
Hemoglobin (Hb) levels at end of treatment (Week 16 and Week 24) were reported. The mean lowest Hb value after treatment starts with a median of 129 gram (g)/Litre (L). The far most frequent hemoglobin class was \>=100 g/L. The purpose of assessing the Hb levels is associated with ribavirin dose. The primary toxicity of ribavirin dose (1000-1200 mg/day, maximum tolerated dose) is anemia with a reduction in hemoglobin levels generally occurring within the first 1-2 weeks of initiating therapy. Decreases in hemoglobin seen in the combination treatment of ribavirin and Interferon-alfa are managed with reduction in ribavirin dosage to 600 mg/day.
Time frame: At Week 16 and Week 24
Mean SF-36 Scores at Baseline and Weeks 16, 24 and 48
Short-Form Health Survey (SF-36) is a 36-item questionnaire measuring eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Where Baseline (BS) is Week 0.
Time frame: At Baseline (Week 0) and Weeks 16, 24 and 48
Mean FSS Scores at Baseline and Weeks 16, 24 and 48
The Fatigue Severity Scale (FSS) is a self-administered instrument that includes 9 items rated on a 7-point scale, measuring fatigue severity. The participants were asked to score each statement, based on how the statement applied to them over the preceding week. The fatigue severity score is the average of the scores on the 9 questions; scores range from 1-7, with lower scores indicating less fatigue. Baseline is defined as Week 0.
Time frame: At Baseline (Week 0) and Weeks 16, 24 and 48
Mean Beschwerdeliste Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 16, 24 and 48
Psychiatric assessment were performed using Beschwerdeliste (BL) questionnaires. BL results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. The BL questionnaire items were scored by calculating the average response to all answered items. Items were graded 1="stark" (affliction is strong) to 4="gar nicht" (not present). The higher the BL score, the less afflictions were present for a participant. Baseline is defined as Week 0.
Time frame: At Baseline (Week 0) and Weeks 16, 24 and 48
Beck Depression Inventory Mean Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 4, 8, 12, 24 and 48
For the psychiatric assessment, the results of the Beck Depression Inventory (BDI) questionnaires were evaluated. BDI results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. BDI is 21 item participant rated inventory evaluates depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicates more depression. Mean scores are presented by visit. Baseline is defined as Week 0.
Time frame: At Baseline (Week 0) and Weeks 4, 8, 12, 24 and 48
Time to Viral Response
Time to viral response was calculated as Date of first negative PCR result after screening - date of PCR screening sample + 1 \[in days\]. Mean of number of days to viral response for overall population were reported.
Time frame: Up to Week 48
A total of 395 participants were recruited at 20 centres in Austria in the study conducted from 20 May 2003 to 10 July 2008.
| Milestone | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| Started | 151 | 144 | 33 | 52 |
| Safety analysis population | 144 | 141 | 30 | 48 |
| Standard analysis population | 115 | 110 | 21 | 26 |
| Completed | 118 | 110 | 22 | 27 |
| Not completed | 33 | 34 | 11 | 25 |
| Withdrew: Adverse event | 5 | 6 | 0 | 0 |
| Withdrew: Extra exclusion criterion amended | 2 | 1 | 1 | 1 |
| Withdrew: Informed consent has been withdrawn | 2 | 2 | 1 | 1 |
| Withdrew: Patient is not able to attend visits | 8 | 9 | 7 | 6 |
| Withdrew: Patient´s compliance | 4 | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 5 | 5 | 0 | 6 |
| Withdrew: Pcr positive at week 24 | 0 | 0 | 0 | 1 |
| Withdrew: Other reason | 7 | 8 | 1 | 8 |
Sustained virological response was defined as the percentage of participants in each group with undetectable Hepatitis C virus-Ribonucleic acid (HCV-RNA) measurement at 24 weeks post completion of the treatment.
| Percentage of participants | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment | 80.9 (72.5 to 87.6) | 78.2 (69.3 to 85.5) | 81.0 (58.1 to 94.6) | 61.5 (40.6 to 79.8) |
Serum Hepatitis C Virus-RNA (HCV-RNA) was done by Polymerase chain reaction (PCR). Samples for a qualitative PCR (AMPLICOR® HCV Test v2.0) were obtained at Week 24 and Week 48. 'G2' and 'G3' indicates Genotype 2 and Genotype 3 respectively.
| Percentage of participants | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| G2, W24, HCV-RNA Positive (n=14,13,3,3) | 7.1 (0.2 to 33.9) | 0.0 (0.0 to 24.7) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| G2, W24, HCV-RNA Negative (n=14,13,3,3) | 92.9 (66.1 to 99.8) | 100 (75.3 to 100) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| G2, W48, HCV-RNA Positive (n=14,13,3,3) | 7.1 (0.2 to 33.9) | 23.1 (5.0 to 53.8) | 66.7 (9.4 to 99.2) | 33.3 (0.8 to 90.6) |
| G2, W48, HCV-RNA Negative (n=14,13,3,3) | 92.9 (66.1 to 99.8) | 76.9 (46.2 to 95.0) | 33.3 (0.8 to 90.6) | 66.7 (9.4 to 99.2) |
| G3, W24, HCV-RNA Positive (n=101,97,18,23) | 1.0 (0.0 to 5.4) | 3.1 (0.6 to 8.8) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| G3, W24, HCV-RNA Negative (n=101,97,18,23) | 99.0 (94.6 to 100) | 96.9 (91.2 to 99.4) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| G3, W48, HCV-RNA Positive (n=101,97,18,23) | 20.8 (13.4 to 30.0) | 21.6 (13.9 to 31.2) | 11.1 (1.4 to 34.7) | 39.1 (19.7 to 61.5) |
| G3, W48, HCV-RNA Negative (n=101,97,18,23) | 79.2 (70.0 to 86.6) | 78.4 (68.8 to 86.1) | 88.9 (65.3 to 98.6) | 60.9 (38.5 to 80.3) |
Virological response at the end of the treatment (ETR) was defined as the percentage of participants with negative qualitative PCR in each group at completion of the treatment. ETR is defined as Week 16 and Week 24.
| Percentage of participants | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| Percentage of Participants With Virological Response at the End of the Treatment | 98.3 (93.9 to 99.8) | 97.3 (92.2 to 99.4) | 95.2 (76.2 to 99.9) | 100 (86.8 to 100) |
Virologic Response was defined as undetectable HCV-RNA levels (determined by AMPLICOR HCV test) at Week 16 and Week 24. Virologic response rates based on genotype (G2 and G3) were reported. ETR is defined as Week 16 and Week 24.
| Percentage of participants | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| G2, W16, Virologic Response (n=14,13,3,3) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 66.7 (9.4 to 99.2) | 100 (29.2 to 100) |
| G2, W24, Virologic Response (n=14,13,3,3) | 92.9 (66.1 to 99.8) | 100 (75.3 to 100) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| G3, W16,Virologic Response (n=101,97,18,23) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 100 (81.5 to 100) | 100 (85.2 to 100) |
| G3, W24,Virologic Response (n=101,97,18,23) | 99.0 (94.6 to 100) | 96.9 (91.2 to 99.4) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
| Number of Participants | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| Any AE | 139 | 138 | 29 | 45 |
| Any SAE | 12 | 18 | 0 | 2 |
Hemoglobin (Hb) levels at end of treatment (Week 16 and Week 24) were reported. The mean lowest Hb value after treatment starts with a median of 129 gram (g)/Litre (L). The far most frequent hemoglobin class was \>=100 g/L. The purpose of assessing the Hb levels is associated with ribavirin dose. The primary toxicity of ribavirin dose (1000-1200 mg/day, maximum tolerated dose) is anemia with a reduction in hemoglobin levels generally occurring within the first 1-2 weeks of initiating therapy. Decreases in hemoglobin seen in the combination treatment of ribavirin and Interferon-alfa are managed with reduction in ribavirin dosage to 600 mg/day.
| g/L | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| At Week 16 | 123.00 (116.00 to 134.00) | 131.00 (120.50 to 140.00) | 129.50 (116.00 to 140.50) | 131.00 (124.00 to 143.00) |
| At Week 24 | 124.00 (115.00 to 133.00) | 130.00 (121.00 to 140.00) | NA (NA to NA) | NA (NA to NA) |
Short-Form Health Survey (SF-36) is a 36-item questionnaire measuring eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. Where Baseline (BS) is Week 0.
| Score on a scale | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| G2, BS, Physical Functioning (n=14,13,3,3) | 87.8 ± 22.1 | 87.9 ± 12.9 | 76.7 ± 10.4 | 69.4 ± 43.2 |
| G2, W16, Physical Functioning (n=14,13,3,3) | NA ± NA | NA ± NA | 63.3 ± 20.8 | 63.3 ± 31.8 |
| G2, W24 Physical Functioning (n=14,13,3,3) | 73.5 ± 20.7 | 79.0 ± 17.9 | NA ± NA | NA ± NA |
| G2,W48, Physical Functioning, (n=14,13,3,3) | 80.6 ± 30.3 | 81.0 ± 20.6 | 82.5 ± 17.7 | 85.0 ± 21.2 |
| G3, BS, Physical Functioning (n=101,97,18,23) | 90.6 ± 13.9 | 85.9 ± 18.3 | 87.2 ± 15.2 | 77.9 ± 26.6 |
| G3, W16, Physical Functioning (n=101,97,18,23) | NA ± NA | NA ± NA | 81.1 ± 14.5 | 69.8 ± 28.1 |
| G3, W24, Physical Functioning (n=101,97,18,23) | 79.6 ± 20.8 | 79.8 ± 22.5 | NA ± NA | NA ± NA |
| G3, W48, Physical Functioning (n=101,97,18,23) | 91.6 ± 13.8 | 89.7 ± 18.6 | 88.9 ± 12.9 | 87.9 ± 12.8 |
| G2, BS,Role Functioning Physical (n=14,13,3,3) | 72.2 ± 38.4 | 88.9 ± 22.0 | 75.0 ± 25.0 | 50.0 ± 70.7 |
| G2,W16,Role Functioning Physical (n=14,13,3,3) | NA ± NA | NA ± NA | 16.7 ± 28.9 | 41.7 ± 52.0 |
| G2,W24,Role Functioning Physical (n=14,13,3,3) | 57.5 ± 31.3 | 50.0 ± 37.3 | NA ± NA | NA ± NA |
| G2,W48,Role Functioning Physical (n=14,13,3,3) | 56.3 ± 47.7 | 88.9 ± 18.2 | 87.5 ± 17.7 | 87.5 ± 17.7 |
| G3, BS,Role Functioning Physical (n=101,97,18,23) | 81.2 ± 30.7 | 73.9 ± 33.0 | 83.3 ± 28.0 | 75.0 ± 34.3 |
| G3,W16,Role Functioning Physical (n=101,97,18,23) | NA ± NA | NA ± NA | 61.1 ± 35.6 | 61.8 ± 40.6 |
| G3,W24,Role Functioning Physical (n=101,97,18,23) | 60.4 ± 40.4 | 63.6 ± 39.5 | NA ± NA | NA ± NA |
| G3,W48,Role Functioning Physical (n=101,97,18,23) | 90.5 ± 23.9 | 85.5 ± 30.2 | 91.7 ± 17.7 | 81.3 ± 31.0 |
| G2, BS, Bodily Pain (n=14,13,3,3) | 78.6 ± 29.0 | 83.0 ± 24.5 | 71.0 ± 25.7 | 61.0 ± 55.2 |
| G2,W16, Bodily Pain (n=14,13,3,3) | NA ± NA | NA ± NA | 61.3 ± 39.0 | 54.3 ± 40.7 |
| G2, W24, Bodily Pain (n=14,13,3,3) | 74.0 ± 28.5 | 55.5 ± 33.3 | NA ± NA | NA ± NA |
| G2, W48, Bodily Pain (n=14,13,3,3) | 76.1 ± 33.7 | 84.0 ± 15.6 | 81.0 ± 26.9 | 81.0 ± 26.9 |
| G3, BS, Bodily Pain (n=101,97,18,23) | 85.5 ± 22.0 | 82.9 ± 19.7 | 73.0 ± 26.1 | 83.6 ± 30.6 |
| G3, W16, Bodily Pain (n=101,97,18,23) | NA ± NA | NA ± NA | 69.6 ± 19.4 | 70.2 ± 31.6 |
| G3, W24, Bodily Pain(n=101,97,18,23) | 76.7 ± 27.3 | 71.5 ± 25.9 | NA ± NA | NA ± NA |
| G3,W48, Bodily Pain (n=101,97,18,23) | 89.5 ± 19.2 | 87.7 ± 23.0 | 84.1 ± 18.1 | 81.9 ± 33.3 |
| G2,BS, General Health (n=14,13,3,3) | 60.4 ± 9.3 | 66.3 ± 17.6 | 62.3 ± 21.1 | 51.0 ± 36.8 |
| G2,W16,General Health (n=14,13,3,3) | NA ± NA | NA ± NA | 42.3 ± 27.5 | 49.0 ± 21.3 |
| G2, W24, General Health (n=14,13,3,3) | 63.2 ± 12.7 | 67.2 ± 20.5 | NA ± NA | NA ± NA |
| G2,W48, General Health (n=14,13,3,3) | 76.3 ± 13.4 | 76.0 ± 14.9 | 53.5 ± 26.2 | 43.5 ± 26.2 |
| G3, BS, General Health (n=101,97,18,23) | 67.2 ± 18.5 | 61.7 ± 19.4 | 56.9 ± 12.9 | 61.1 ± 23.6 |
| G3, W16, General Health (n=101,97,18,23) | NA ± NA | NA ± NA | 58.3 ± 20.4 | 63.6 ± 19.9 |
| G3, W24, General Health (n=101,97,18,23) | 68.1 ± 18.1 | 59.5 ± 21.3 | NA ± NA | NA ± NA |
| G3, W48, General Health (n=101,97,18,23) | 73.9 ± 16.0 | 70.5 ± 21.6 | 70.2 ± 19.5 | 63.0 ± 26.0 |
| G2, BS, Vitality (n=14,13,3,3) | 58.1 ± 20.5 | 62.2 ± 11.4 | 43.3 ± 18.9 | 35.0 ± 49.5 |
| G2,W16, Vitality (n=14,13,3,3) | NA ± NA | NA ± NA | 25.0 ± 21.8 | 30.6 ± 14.2 |
| G2, W24, Vitality (n=14,13,3,3) | 38.5 ± 23.0 | 39.5 ± 22.0 | NA ± NA | NA ± NA |
| G2,W48, Vitality (n=14,13,3,3) | 58.1 ± 19.3 | 63.9 ± 15.0 | 57.5 ± 24.7 | 45.0 ± 35.4 |
| G3,BS, Vitality (n=101,97,18,23) | 55.8 ± 21.1 | 51.9 ± 21.4 | 51.7 ± 24.9 | 49.4 ± 24.8 |
| G3,W16, Vitality (n=101,97,18,23) | NA ± NA | NA ± NA | 46.1 ± 19.5 | 43.5 ± 18.1 |
| G3,W24, Vitality (n=101,97,18,23) | 46.9 ± 24.4 | 45.5 ± 23.8 | NA ± NA | NA ± NA |
| G3, W48, Vitality (n=101,97,18,23) | 63.4 ± 19.1 | 58.7 ± 20.2 | 70.6 ± 15.7 | 60.1 ± 18.9 |
| G2, BS, Social Functioning (n=14,13,3,3) | 80.6 ± 21.8 | 93.8 ± 10.6 | 75.0 ± 12.5 | 56.3 ± 44.2 |
| G2, W16, Social Functioning (n=14,13,3,3) | NA ± NA | NA ± NA | 50.0 ± 43.3 | 58.3 ± 26.0 |
| G2,W24, Social Functioning (n=14,13,3,3) | 63.8 ± 32.0 | 76.3 ± 28.5 | NA ± NA | NA ± NA |
| G2,W48, Social Functioning (n=14,13,3,3) | 89.1 ± 15.6 | 86.1 ± 15.9 | 81.3 ± 26.5 | 81.3 ± 26.5 |
| G3,BS, Social Functioning (n=101,97,18,23) | 83.8 ± 19.5 | 77.2 ± 23.5 | 86.1 ± 20.2 | 84.7 ± 20.8 |
| G3, W16, Social Functioning (n=101,97,18,23) | NA ± NA | NA ± NA | 63.9 ± 20.2 | 66.9 ± 30.3 |
| G3,W24, Social Functioning (n=101,97,18,23) | 68.8 ± 26.7 | 72.1 ± 26.3 | NA ± NA | NA ± NA |
| G3, W48, Social Functioning (n=101,97,18,23) | 86.6 ± 21.0 | 81.6 ± 27.0 | 87.5 ± 18.8 | 78.7 ± 26.8 |
| G2, BS, Role Functioning Emotional (n=14,13,3,3) | 74.1 ± 36.4 | 88.9 ± 23.6 | 77.8 ± 19.2 | 50.0 ± 70.7 |
| G2,W16, Role Functioning Emotional (n=14,13,3,3) | NA ± NA | NA ± NA | 33.3 ± 33.3 | 44.4 ± 50.9 |
| G2,W24, Role Functioning Emotional (n=14,13,3,3) | 56.7 ± 38.7 | 43.3 ± 38.7 | NA ± NA | NA ± NA |
| G2,W48, Role Functioning Emotional (n=14,13,3,3) | 60.4 ± 37.7 | 85.2 ± 24.2 | 100.0 ± 0.0 | 83.3 ± 23.6 |
| G3,BS,Role Functioning Emotional (n=101,97,18,23) | 83.1 ± 29.7 | 73.2 ± 36.1 | 70.4 ± 35.1 | 68.5 ± 40.4 |
| G3,W16,Role Functioning Emotional (n=101,97,18,23) | NA ± NA | NA ± NA | 63.0 ± 35.1 | 60.8 ± 41.2 |
| G3,W24,Role Functioning Emotional (n=101,97,18,23) | 61.0 ± 41.0 | 57.4 ± 44.6 | NA ± NA | NA ± NA |
| G3,W48,Role Functioning Emotional (n=101,97,18,23) | 90.9 ± 23.8 | 84.2 ± 33.4 | 88.9 ± 23.6 | 79.2 ± 36.3 |
| G2,BS, Mental Health (n=14,13,3,3) | 66.5 ± 13.5 | 73.2 ± 14.9 | 57.3 ± 18.0 | 58.0 ± 48.1 |
| G2,W16, Mental Health (n=14,13,3,3) | NA ± NA | NA ± NA | 42.7 ± 20.1 | 49.3 ± 19.7 |
| G2,W24, Mental Health (n=14,13,3,3) | 59.2 ± 22.5 | 64.8 ± 21.2 | NA ± NA | NA ± NA |
| G2,W48, Mental Health (n=14,13,3,3) | 66.3 ± 19.2 | 76.1 ± 14.3 | 58.5 ± 37.5 | 70.0 ± 31.1 |
| G3,BS, Mental Health (n=101,97,18,23) | 69.2 ± 16.6 | 67.8 ± 17.2 | 63.6 ± 17.4 | 59.6 ± 25.4 |
| G3,W16, Mental Health (n=101,97,18,23) | NA ± NA | NA ± NA | 56.4 ± 15.0 | 55.5 ± 19.7 |
| G3,W24, Mental Health (n=101,97,18,23) | 63.0 ± 19.9 | 63.2 ± 21.0 | NA ± NA | NA ± NA |
| G3, W48, Mental Health (n=101,97,18,23) | 70.5 ± 15.7 | 68.8 ± 20.9 | 68.0 ± 20.2 | 64.1 ± 19.7 |
| G2,BS,Reported Health Transition (n=14,13,3,3) | 2.7 ± 0.5 | 3.0 ± 0.8 | 3.7 ± 0.6 | 3.0 ± 2.8 |
| G2,W16,Reported Health Transition (n=14,13,3,3) | NA ± NA | NA ± NA | 4.0 ± 1.0 | 3.0 ± 1.0 |
| G2,W24,Reported Health Transition (n=14,13,3,3) | 2.6 ± 1.0 | 3.7 ± 0.8 | NA ± NA | NA ± NA |
| G2,W48,Reported Health Transition (n=14,13,3,3) | 1.8 ± 0.9 | 1.9 ± 0.8 | 2.0 ± 0.0 | 2.5 ± 0.7 |
| G3,BS,Reported Health Transition (n=101,97,18,23) | 2.8 ± 1.1 | 2.9 ± 1.0 | 2.9 ± 0.9 | 2.8 ± 1.1 |
| G3,W16,Reported Health Transition (n=101,97,18,23) | NA ± NA | NA ± NA | 3.3 ± 1.1 | 2.9 ± 1.5 |
| G3,W24,Reported Health Transition (n=101,97,18,23) | 3.0 ± 1.3 | 2.7 ± 1.4 | NA ± NA | NA ± NA |
| G3,W48,Reported Health Transition (n=101,97,18,23) | 1.7 ± 0.9 | 1.9 ± 1.1 | 2.3 ± 1.2 | 2.2 ± 0.9 |
The Fatigue Severity Scale (FSS) is a self-administered instrument that includes 9 items rated on a 7-point scale, measuring fatigue severity. The participants were asked to score each statement, based on how the statement applied to them over the preceding week. The fatigue severity score is the average of the scores on the 9 questions; scores range from 1-7, with lower scores indicating less fatigue. Baseline is defined as Week 0.
| Score on a scale | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| G2, BS (n=14,13,3,3) | 3.5 ± 1.2 | 3.4 ± 1.1 | 4.9 ± 0.3 | 3.9 ± 2.9 |
| G2, W16 (n=14,13,3,3) | NA ± NA | NA ± NA | 6.2 ± 0.5 | 3.7 ± 1.8 |
| G2, W24 (n=14,13,3,3) | 4.4 ± 1.3 | 4.4 ± 1.2 | NA ± NA | NA ± NA |
| G2, W48 (n=14,13,3,3) | 3.4 ± 1.6 | 3.5 ± 1.2 | 4.5 ± 0.4 | 3.2 ± 2.8 |
| G3,BS(n=101,97,18,23) | 3.6 ± 1.2 | 3.8 ± 1.6 | 3.4 ± 1.5 | 3.5 ± 1.6 |
| G3, W16, (n=101,97,18,23) | NA ± NA | NA ± NA | 4.0 ± 1.6 | 4.3 ± 1.5 |
| G3, W24 (n=101,97,18,23) | 4.1 ± 1.7 | 4.1 ± 1.7 | NA ± NA | NA ± NA |
| G3, W48 (n=101,97,18,23) | 3.0 ± 1.3 | 3.2 ± 1.6 | 2.4 ± 1.6 | 3.7 ± 1.8 |
Psychiatric assessment were performed using Beschwerdeliste (BL) questionnaires. BL results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. The BL questionnaire items were scored by calculating the average response to all answered items. Items were graded 1="stark" (affliction is strong) to 4="gar nicht" (not present). The higher the BL score, the less afflictions were present for a participant. Baseline is defined as Week 0.
| Score on a scale | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| G2 ,BL, BS (n=14,13,3,3) | 3.3 ± 0.4 | 3.4 ± 0.5 | 3.0 ± NA | NA ± NA |
| G2, BL,W4 (n=14,13,3,3) | 3.1 ± 0.7 | 3.3 ± 0.4 | NA ± NA | 3.8 ± NA |
| G2, BL, W8 (n=14,13,3,3) | 3.4 ± 0.7 | 3.6 ± 0.5 | NA ± NA | NA ± NA |
| G2, BL, W12 (n=14,13,3,3) | 3.5 ± 0.7 | 3.3 ± 0.5 | 3.0 ± NA | NA ± NA |
| G2, BL,W24 (n=14,13,3,3) | 2.9 ± 0.6 | 3.2 ± 0.4 | NA ± NA | NA ± NA |
| G2, BL,W48 (n=14,13,3,3) | 3.4 ± 0.4 | 3.4 ± 0.4 | 3.2 ± NA | 4.0 ± NA |
| G3, BL,BS(n=101,97,18,23) | 3.3 ± 0.4 | 3.3 ± 0.4 | 3.2 ± 0.2 | 3.3 ± 0.4 |
| G3, BL,W4 (n=101,97,18,23) | 3.4 ± 0.6 | 3.0 ± 0.4 | NA ± NA | NA ± NA |
| G3, BL,W8 (n=101,97,18,23) | 3.3 ± 0.6 | 3.0 ± 0.5 | 2.6 ± 0.3 | 3.7 ± NA |
| G3, BL,W12 (n=101,97,18,23) | 3.2 ± 0.6 | 3.1 ± 0.5 | 3.2 ± 0.3 | 3.0 ± 0.5 |
| G3,BL,W24 (n=101,97,18,23) | 3.2 ± 0.5 | 3.2 ± 0.5 | NA ± NA | NA ± NA |
| G3,BL,W48 (n=101,97,18,23) | 3.6 ± 0.4 | 3.5 ± 0.4 | 3.4 ± 0.5 | 3.3 ± 0.5 |
For the psychiatric assessment, the results of the Beck Depression Inventory (BDI) questionnaires were evaluated. BDI results were analyzed descriptively by visit, treatment group, genotype and opioid maintenance therapy status. BDI is 21 item participant rated inventory evaluates depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicates more depression. Mean scores are presented by visit. Baseline is defined as Week 0.
| Score on a scale | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| G2,BDI,BS (n=14,13,3,3) | 8.2 ± 4.0 | 5.4 ± 6.4 | 9.0 ± NA | NA ± NA |
| G2,BDI,W4 (n=14,13,3,3) | 10.7 ± 12.5 | 8.8 ± 9.7 | NA ± NA | 3.0 ± NA |
| G2,BDI,W8 (n=14,13,3,3) | 10.0 ± 9.9 | 3.0 ± 4.2 | NA ± NA | NA ± NA |
| G2,BDI,W12 (n=14,13,3,3) | 8.0 ± 9.9 | 8.5 ± 7.8 | 8.0 ± NA | NA ± NA |
| G2,BDI,W24 (n=14,13,3,3) | 11.5 ± 9.4 | 7.6 ± 4.7 | NA ± NA | NA ± NA |
| G2,BDI,W48 (n=14,13,3,3) | 3.8 ± 2.3 | 4.0 ± 5.1 | 4.0 ± NA | 1.0 ± NA |
| G3,BDI,BS (n=101,97,18,23) | 7.1 ± 6.4 | 8.9 ± 7.7 | 8.0 ± 5.5 | 7.0 ± 3.7 |
| G3,BDI,W4 (n=101,97,18,23) | 7.9 ± 8.4 | 10.8 ± 8.1 | NA ± NA | NA ± NA |
| G3,BDI,W8 (n=101,97,18,23) | 8.2 ± 8.5 | 12.7 ± 11.6 | 20.0 ± NA | NA ± NA |
| G3,BDI,W12 (n=101,97,18,23) | 7.8 ± 7.3 | 11.4 ± 8.0 | 4.8 ± 5.3 | 15.0 ± 9.6 |
| G3,BDI,W24 (n=101,97,18,23) | 8.0 ± 7.6 | 9.0 ± 7.9 | NA ± NA | NA ± NA |
| G3,BDI,W48 (n=101,97,18,23) | 3.6 ± 4.7 | 6.7 ± 8.0 | 5.4 ± 7.7 | 6.6 ± 7.9 |
Time to viral response was calculated as Date of first negative PCR result after screening - date of PCR screening sample + 1 \[in days\]. Mean of number of days to viral response for overall population were reported.
| Days | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) |
|---|---|---|---|---|
| Time to Viral Response | 165.1 ± 73.6 | 165.0 ± 78.8 | 114.5 ± 76.7 | 122.8 ± 56.4 |
Collected over Up to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ribavirin 800 mg/24W | — | 12/144 (8.3%) | 133/144 (92.4%) |
| Ribavirin 400 mg/24W | — | 18/141 (12.8%) | 128/141 (90.8%) |
| Ribavirin 800 mg/16W | — | 0/30 (0%) | 27/30 (90%) |
| Ribavirin 400 mg/16W | — | 2/48 (4.2%) | 38/48 (79.2%) |
| Event | Ribavirin 800 mg/24W | Ribavirin 400 mg/24W | Ribavirin 800 mg/16W | Ribavirin 400 mg/16W |
|---|---|---|---|---|
| Abdominal pain nosGastrointestinal disorders | 0/144 | 0/141 | 0/30 | 1/48 |
| AnorexiaMetabolism and nutrition disorders | 0/144 | 0/141 | 0/30 | 1/48 |
| Abdominal painGastrointestinal disorders | 0/144 | 2/141 | 0/30 | 0/48 |
| PneumoniaInfections and infestations | 2/144 | 0/141 | 0/30 | 0/48 |
| Perianal abscessInfections and infestations | 1/144 | 1/141 | 0/30 | 0/48 |
| AbscessInfections and infestations | 0/144 | 1/141 | 0/30 | 0/48 |
| Bartholin's abscessInfections and infestations | 0/144 | 1/141 | 0/30 | 0/48 |
| Right otitis externaInfections and infestations | 0/144 | 1/141 | 0/30 | 0/48 |
| Septic phlebitisInfections and infestations | 0/144 | 1/141 | 0/30 | 0/48 |
| DizzinessNervous system disorders | 0/144 | 1/141 | 0/30 | 0/48 |
| Event | Ribavirin 800 mg/24W | Ribavirin 400 mg/24W | Ribavirin 800 mg/16W | Ribavirin 400 mg/16W |
|---|---|---|---|---|
| Flu like symptomsGeneral disorders | 54/144 | 54/141 | 6/30 | 8/48 |
| FatigueGeneral disorders | 50/144 | 53/141 | 11/30 | 15/48 |
| FeverGeneral disorders | 17/144 | 13/141 | 8/30 | 9/48 |
| CephalgiaNervous system disorders | 20/144 | 26/141 | 7/30 | 8/48 |
| DepressionPsychiatric disorders | 26/144 | 24/141 | 3/30 | 6/48 |
| Hair lossSkin and subcutaneous tissue disorders | 20/144 | 20/141 | 2/30 | 8/48 |
| Appetite lostMetabolism and nutrition disorders | 20/144 | 17/141 | 2/30 | 3/48 |
| NauseaGastrointestinal disorders | 13/144 | 15/141 | 4/30 | 2/48 |
| LeucopeniaBlood and lymphatic system disorders | 6/144 | 5/141 | 4/30 | 1/48 |
| Sleep disorderPsychiatric disorders | 13/144 | 10/141 | 3/30 | 6/48 |
| Age, Continuous(Years) | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) | Total |
|---|---|---|---|---|---|
| Mean | 36.8 ± 11.1 | 35.7 ± 10.2 | 35.8 ± 11.2 | 35.2 ± 10.0 | 36.1 ± 10.6 |
| Sex: Female, Male(Participants) | Peginterferon/Ribavirin 800 mg (24 Weeks) | Peginterferon/Ribavirin 400 mg (24 Weeks) | Peginterferon/Ribavirin 800 mg (16 Weeks) | Peginterferon/Ribavirin 400 mg (16 Weeks) | Total |
|---|---|---|---|---|---|
| Female | 62 | 54 | 14 | 21 | 151 |
| Male | 89 | 90 | 19 | 31 | 229 |
The record gives a start of May 2003, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 8 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin